YAP1 and cutaneous melanoma: Blocking the YAP/TAZ pathway may be beneficial to overcome MAPK-inhibitor resistance, as YAP/TAZ knockdown restored sensitivity to BRAF-inhibitors in previously resistant cutaneous melanoma cell lines,66 and VP caused reduced tumor formation in a mouse model with BRAF-inhibitor-resistant skin melanoma cells.67